Verona reports positive data from CF trial

Verona Pharma Plc has reported positive top-line data from a Phase 2a trial of its inhaled drug for patients with cystic fibrosis, a rare inherited disease that causes impaired lung function and premature death. The data showed an improvement in lung function that was statistically significant.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom